U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Locally Advanced Oropharyngeal Squamous Cell Carcinoma

MedGen UID:
1693245
•Concept ID:
C5206858
•
Neoplastic Process

Definition

An oropharyngeal squamous cell carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVLocally Advanced Oropharyngeal Squamous Cell Carcinoma

Professional guidelines

PubMed

Cervical nodal level V can safely be omitted in the treatment of locally advanced oropharyngeal squamous cell carcinoma with definitive IMRT.
Gutiontov S, Leeman J, Lok B, Romesser P, Riaz N, Tsai CJ, Lee N, McBride S
Oral Oncol 2016 Jul;58:27-31. Epub 2016 May 27 doi: 10.1016/j.oraloncology.2016.04.011. PMID: 27311399Free PMC Article
De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma.
Masterson L, Moualed D, Masood A, Dwivedi RC, Benson R, Sterling JC, Rhodes KM, Sudhoff H, Jani P, Goon P
Cochrane Database Syst Rev 2014 Feb 15;2014(2):CD010271. doi: 10.1002/14651858.CD010271.pub2. PMID: 24532092Free PMC Article
Intensity modulated radiotherapy (IMRT) in the management of locally advanced oropharyngeal squamous cell carcinomata (SCC): disease control and functional outcome using the therapy outcome measure (TOM) score--report from a single U.K. institution.
Ingle CJ, Yip K, Caskie V, Dyson C, Ford A, Scrase CD
Head Neck Oncol 2010 Oct 14;2:28. doi: 10.1186/1758-3284-2-28. PMID: 20946673Free PMC Article

Recent clinical studies

Etiology

Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma.
Wise-Draper TM, Gulati S, Palackdharry S, Hinrichs BH, Worden FP, Old MO, Dunlap NE, Kaczmar JM, Patil Y, Riaz MK, Tang A, Mark J, Zender C, Gillenwater AM, Bell D, Kurtzweil N, Mathews M, Allen CL, Mierzwa ML, Casper K, Jandarov R, Medvedovic M, Lee JJ, Harun N, Takiar V, Gillison M
Clin Cancer Res 2022 Apr 1;28(7):1345-1352. doi: 10.1158/1078-0432.CCR-21-3351. PMID: 35338369Free PMC Article
Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).
Ferris RL, Flamand Y, Weinstein GS, Li S, Quon H, Mehra R, Garcia JJ, Chung CH, Gillison ML, Duvvuri U, O'Malley BW Jr, Ozer E, Thomas GR, Koch WM, Gross ND, Bell RB, Saba NF, Lango M, Méndez E, Burtness B
J Clin Oncol 2022 Jan 10;40(2):138-149. Epub 2021 Oct 26 doi: 10.1200/JCO.21.01752. PMID: 34699271Free PMC Article
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.
Uppaluri R, Campbell KM, Egloff AM, Zolkind P, Skidmore ZL, Nussenbaum B, Paniello RC, Rich JT, Jackson R, Pipkorn P, Michel LS, Ley J, Oppelt P, Dunn GP, Barnell EK, Spies NC, Lin T, Li T, Mulder DT, Hanna Y, Cirlan I, Pugh TJ, Mudianto T, Riley R, Zhou L, Jo VY, Stachler MD, Hanna GJ, Kass J, Haddad R, Schoenfeld JD, Gjini E, Lako A, Thorstad W, Gay HA, Daly M, Rodig SJ, Hagemann IS, Kallogjeri D, Piccirillo JF, Chernock RD, Griffith M, Griffith OL, Adkins DR
Clin Cancer Res 2020 Oct 1;26(19):5140-5152. Epub 2020 Jul 14 doi: 10.1158/1078-0432.CCR-20-1695. PMID: 32665297Free PMC Article
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ; KEYNOTE-040 investigators
Lancet 2019 Jan 12;393(10167):156-167. Epub 2018 Nov 30 doi: 10.1016/S0140-6736(18)31999-8. PMID: 30509740
Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment.
Marur S, Forastiere AA
Mayo Clin Proc 2016 Mar;91(3):386-96. doi: 10.1016/j.mayocp.2015.12.017. PMID: 26944243

Diagnosis

Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update.
Bhatia A, Burtness B
Drugs 2023 Feb;83(3):217-248. Epub 2023 Jan 16 doi: 10.1007/s40265-023-01835-2. PMID: 36645621
Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design.
Bourhis J, Burtness B, Licitra LF, Nutting C, Schoenfeld JD, Omar M, Bouisset F, Nauwelaerts H, Urfer Y, Zanna C, Cohen EE
Future Oncol 2022 May;18(14):1669-1678. Epub 2022 Feb 17 doi: 10.2217/fon-2021-1634. PMID: 35172587
Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy.
Parmar A, Macluskey M, Mc Goldrick N, Conway DI, Glenny AM, Clarkson JE, Worthington HV, Chan KK
Cochrane Database Syst Rev 2021 Dec 20;12(12):CD006386. doi: 10.1002/14651858.CD006386.pub4. PMID: 34929047Free PMC Article
Head and neck cancer.
Mody MD, Rocco JW, Yom SS, Haddad RI, Saba NF
Lancet 2021 Dec 18;398(10318):2289-2299. Epub 2021 Sep 22 doi: 10.1016/S0140-6736(21)01550-6. PMID: 34562395
Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment.
Marur S, Forastiere AA
Mayo Clin Proc 2016 Mar;91(3):386-96. doi: 10.1016/j.mayocp.2015.12.017. PMID: 26944243

Therapy

Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment.
Ruffin AT, Li H, Vujanovic L, Zandberg DP, Ferris RL, Bruno TC
Nat Rev Cancer 2023 Mar;23(3):173-188. Epub 2022 Dec 1 doi: 10.1038/s41568-022-00531-9. PMID: 36456755Free PMC Article
Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).
Ferris RL, Flamand Y, Weinstein GS, Li S, Quon H, Mehra R, Garcia JJ, Chung CH, Gillison ML, Duvvuri U, O'Malley BW Jr, Ozer E, Thomas GR, Koch WM, Gross ND, Bell RB, Saba NF, Lango M, Méndez E, Burtness B
J Clin Oncol 2022 Jan 10;40(2):138-149. Epub 2021 Oct 26 doi: 10.1200/JCO.21.01752. PMID: 34699271Free PMC Article
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, Kojima T, Metges JP, Li Z, Kim SB, Cho BC, Mansoor W, Li SH, Sunpaweravong P, Maqueda MA, Goekkurt E, Hara H, Antunes L, Fountzilas C, Tsuji A, Oliden VC, Liu Q, Shah S, Bhagia P, Kato K; KEYNOTE-590 Investigators
Lancet 2021 Aug 28;398(10302):759-771. doi: 10.1016/S0140-6736(21)01234-4. PMID: 34454674
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ; KEYNOTE-040 investigators
Lancet 2019 Jan 12;393(10167):156-167. Epub 2018 Nov 30 doi: 10.1016/S0140-6736(18)31999-8. PMID: 30509740
Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment.
Marur S, Forastiere AA
Mayo Clin Proc 2016 Mar;91(3):386-96. doi: 10.1016/j.mayocp.2015.12.017. PMID: 26944243

Prognosis

Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial.
Tao Y, Sun XS, Pointreau Y, Le Tourneau C, Sire C, Kaminsky MC, Coutte A, Alfonsi M, Calderon B, Boisselier P, Martin L, Miroir J, Ramee JF, Delord JP, Clatot F, Rolland F, Villa J, Magne N, Elicin O, Gherga E, Nguyen F, Lafond C, Bera G, Calugaru V, Geoffrois L, Chauffert B, Damstrup L, Crompton P, Ennaji A, Gollmer K, Nauwelaerts H, Bourhis J
Eur J Cancer 2023 Apr;183:24-37. Epub 2023 Jan 9 doi: 10.1016/j.ejca.2022.12.015. PMID: 36796234
Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update.
Bhatia A, Burtness B
Drugs 2023 Feb;83(3):217-248. Epub 2023 Jan 16 doi: 10.1007/s40265-023-01835-2. PMID: 36645621
Integrated multi-omics analysis identifies CD73 as a prognostic biomarker and immunotherapy response predictor in head and neck squamous cell carcinoma.
Shen A, Ye Y, Chen F, Xu Y, Zhang Z, Zhao Q, Zeng ZL
Front Immunol 2022;13:969034. Epub 2022 Nov 16 doi: 10.3389/fimmu.2022.969034. PMID: 36466881Free PMC Article
Pembrolizumab in the first-line treatment of advanced head and neck cancer.
de Sousa LG, Ferrarotto R
Expert Rev Anticancer Ther 2021 Dec;21(12):1321-1331. Epub 2021 Nov 2 doi: 10.1080/14737140.2021.1996228. PMID: 34689660
Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.
Sun XS, Tao Y, Le Tourneau C, Pointreau Y, Sire C, Kaminsky MC, Coutte A, Alfonsi M, Boisselier P, Martin L, Miroir J, Ramee JF, Delord JP, Clatot F, Rolland F, Villa J, Magne N, Elicin O, Gherga E, Nguyen F, Lafond C, Bera G, Calugaru V, Geoffrois L, Chauffert B, Zubel A, Zanna C, Brienza S, Crompton P, Rouits E, Gollmer K, Szyldergemajn S, Bourhis J
Lancet Oncol 2020 Sep;21(9):1173-1187. Epub 2020 Aug 3 doi: 10.1016/S1470-2045(20)30327-2. PMID: 32758455

Clinical prediction guides

Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).
Ferris RL, Flamand Y, Weinstein GS, Li S, Quon H, Mehra R, Garcia JJ, Chung CH, Gillison ML, Duvvuri U, O'Malley BW Jr, Ozer E, Thomas GR, Koch WM, Gross ND, Bell RB, Saba NF, Lango M, Méndez E, Burtness B
J Clin Oncol 2022 Jan 10;40(2):138-149. Epub 2021 Oct 26 doi: 10.1200/JCO.21.01752. PMID: 34699271Free PMC Article
Pembrolizumab in the first-line treatment of advanced head and neck cancer.
de Sousa LG, Ferrarotto R
Expert Rev Anticancer Ther 2021 Dec;21(12):1321-1331. Epub 2021 Nov 2 doi: 10.1080/14737140.2021.1996228. PMID: 34689660
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, Kojima T, Metges JP, Li Z, Kim SB, Cho BC, Mansoor W, Li SH, Sunpaweravong P, Maqueda MA, Goekkurt E, Hara H, Antunes L, Fountzilas C, Tsuji A, Oliden VC, Liu Q, Shah S, Bhagia P, Kato K; KEYNOTE-590 Investigators
Lancet 2021 Aug 28;398(10302):759-771. doi: 10.1016/S0140-6736(21)01234-4. PMID: 34454674
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Lee NY, Ferris RL, Psyrri A, Haddad RI, Tahara M, Bourhis J, Harrington K, Chang PM, Lin JC, Razaq MA, Teixeira MM, Lövey J, Chamois J, Rueda A, Hu C, Dunn LA, Dvorkin MV, De Beukelaer S, Pavlov D, Thurm H, Cohen E
Lancet Oncol 2021 Apr;22(4):450-462. doi: 10.1016/S1470-2045(20)30737-3. PMID: 33794205
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.
Uppaluri R, Campbell KM, Egloff AM, Zolkind P, Skidmore ZL, Nussenbaum B, Paniello RC, Rich JT, Jackson R, Pipkorn P, Michel LS, Ley J, Oppelt P, Dunn GP, Barnell EK, Spies NC, Lin T, Li T, Mulder DT, Hanna Y, Cirlan I, Pugh TJ, Mudianto T, Riley R, Zhou L, Jo VY, Stachler MD, Hanna GJ, Kass J, Haddad R, Schoenfeld JD, Gjini E, Lako A, Thorstad W, Gay HA, Daly M, Rodig SJ, Hagemann IS, Kallogjeri D, Piccirillo JF, Chernock RD, Griffith M, Griffith OL, Adkins DR
Clin Cancer Res 2020 Oct 1;26(19):5140-5152. Epub 2020 Jul 14 doi: 10.1158/1078-0432.CCR-20-1695. PMID: 32665297Free PMC Article

Recent systematic reviews

Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy.
Parmar A, Macluskey M, Mc Goldrick N, Conway DI, Glenny AM, Clarkson JE, Worthington HV, Chan KK
Cochrane Database Syst Rev 2021 Dec 20;12(12):CD006386. doi: 10.1002/14651858.CD006386.pub4. PMID: 34929047Free PMC Article
A systematic review of proteomic biomarkers in oral squamous cell cancer.
Pillai J, Chincholkar T, Dixit R, Pandey M
World J Surg Oncol 2021 Oct 28;19(1):315. doi: 10.1186/s12957-021-02423-y. PMID: 34711249Free PMC Article
What is the prognostic impact of FDG PET in locally advanced head and neck squamous cell carcinoma treated with concomitant chemo-radiotherapy? A systematic review and meta-analysis.
Bonomo P, Merlotti A, Olmetto E, Bianchi A, Desideri I, Bacigalupo A, Franco P, Franzese C, Orlandi E, Livi L, Caini S
Eur J Nucl Med Mol Imaging 2018 Nov;45(12):2122-2138. Epub 2018 Jun 9 doi: 10.1007/s00259-018-4065-5. PMID: 29948105Free PMC Article
Locally advanced squamous cell carcinoma of the head and neck: A systematic review and Bayesian network meta-analysis of the currently available treatment options.
Iocca O, Farcomeni A, Di Rocco A, Di Maio P, Golusinski P, Pardiñas López S, Savo A, Pellini R, Spriano G
Oral Oncol 2018 May;80:40-51. Epub 2018 Mar 27 doi: 10.1016/j.oraloncology.2018.03.001. PMID: 29706187
The evidence on effectiveness of weekly vs triweekly cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC): a systematic review and meta-analysis.
Jacinto JK, Co J, Mejia MB, Regala EE
Br J Radiol 2017 Nov;90(1079):20170442. doi: 10.1259/bjr.20170442. PMID: 29053029Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...